Hims & Hers Health, Inc. (HIMS)
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie NYSE: ABBV, Eli Lilly NYSE: LLY, Pfizer NYSE: PFE, and Merck NYSE: MRK—and their lineup of game-changing drugs—receive the lion's share of attention.
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?
HIMS faces rising regulatory strain, margin pressure and competition despite strong revenue momentum.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and cosmetics, that address acne, hyperpigmentation and eczema and range in price from about $29 to around $59.
Hims & Hers names ex-FDA official Deb Autor as first policy chief
Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.
Hims & Hers Bets on Lab Testing to Boost Growth
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
HIMS deepens its technology-enabled care model with new offerings in GLP-1 weight loss, hormone health, and custom treatments.
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hence, it see longer-term financial leverage from scaling that business model. The "active discussions" with Novo Nordisk are a cherry on top but we see green shoots outside of weight-loss drugs that'll support growth.
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
